Enlivex Ltd.

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Enlivex Ltd. and other ETFs, options, and stocks.

About ENLV

Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. 

CEO
Oren Hershkovitz
CEOOren Hershkovitz
Employees
34
Employees34
Headquarters
Ness Ziona, Tel Aviv
HeadquartersNess Ziona, Tel Aviv
Founded
2012
Founded2012
Employees
34
Employees34

ENLV Key Statistics

Market cap
174.64M
Market cap174.64M
Price-Earnings ratio
0.03
Price-Earnings ratio0.03
Dividend yield
Dividend yield
Average volume
196.62K
Average volume196.62K
High today
$0.7399
High today$0.7399
Low today
$0.72
Low today$0.72
Open price
$0.737
Open price$0.737
Volume
70.82K
Volume70.82K
52 Week high
$2.10
52 Week high$2.10
52 Week low
$0.66
52 Week low$0.66

Stock Snapshot

With a market cap of 174.64M, Enlivex Ltd.(ENLV) trades at $0.74. The stock has a price-to-earnings ratio of 0.03.

On 2026-05-22, Enlivex Ltd.(ENLV) stock moved within a range of $0.72 to $0.74. With shares now at $0.74, the stock is trading +2.2% above its intraday low and -0.6% below the session's peak.

Trading volume for Enlivex Ltd.(ENLV) stock has reached 70.82K, versus its average volume of 196.62K.

The stock's 52-week range extends from a low of $0.66 to a high of $2.10.

The stock's 52-week range extends from a low of $0.66 to a high of $2.10.

ENLV News

TipRanks 2d
Enlivex Advances Allocetra Into Mid-Stage Knee Osteoarthritis Trial, Keeping Investor Focus on ENLV

Enlivex Therapeutics (ENLV) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper...

Investing.com 4d
Enlivex doses first U.S. patient in knee osteoarthritis trial - Investing.com

...

Enlivex doses first U.S. patient in knee osteoarthritis trial - Investing.com
TipRanks 4d
Enlivex Doses First U.S. Patient in Phase 2b Allocetra Trial for Knee Osteoarthritis

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

More ENLV News

TipRanks 4d
Enlivex Therapeutics doses first patient in Allocetra trial

Enlivex announced the dosing of the first patient at a United States clinical site in the Phase 2b clinical trial of Allocetra for the treatment of patients wit...

People also own

Based on the portfolios of people who own ENLV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.